A Public Health Analysis on Gaps in Disease Monitoring and Opportunities for Improved Care for the Management of Hepatitis B and C
Authors:
Open Access
- 16 January 2018
- journal article
- review article
- Published by Springer Nature in Cureus
- Vol. 10 (1) , e2077
Abstract
Hepatitis B and Hepatitis C have been major disease-causing agents among humans since they were discovered in the 1960s. Both cause jaundice-like symptoms initially but their prognosis and treatment are somehow different and depend upon many demographic details, such as the age and susceptibility of the patients and any other comorbid conditions. They clinically present primarily with hepatitis and can have many adverse effects or even be life-threatening at times, if not treated properly. However, their epidemiological background and findings in terms of morbidity, mortality, and case fatality rates are different. The disease burden, impact on the healthcare system, and prevention of the two diseases are quite different. The treatment and management options along with the prevention and control measures share unique strategies for handling the two diseases. The purpose of this review is to highlight the gaps in disease monitoring and to find ways and opportunities that can lead to improved care and better management of Hepatitis B and C locally and globally. Online databases were searched and peer-reviewed articles were selected. Key issues identified were lack of education globally in resource-limited settings, leading to a decreased understanding of the potential hazards associated with needle sharing and lack of access to healthcare because of a lack of insurance. The failure of compliance with vaccination leads to an increase in mother-to-child transmission (MTCT)-related infections. Increased global travel demands a systematic program in most immigrant-receiving countries to screen for hepatitis B virus (HBV)/hepatitis c virus (HCV) infections. Delayed U.S. Food and Drug Administration (FDA) licensing for new drugs hampers the treatment of chronic Hepatitis-B (CHB) among children. With the advancement in science, an effective vaccine against HCV will definitely help in eradicating the infection.Keywords
This publication has 33 references indexed in Scilit:
- Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional studyThe Lancet Infectious Diseases, 2015
- Treatment of hepatitis B and C in children.2014
- Treatment of Hepatitis CJAMA, 2014
- Progress Toward Prevention of Transfusion-Transmitted Hepatitis B and Hepatitis C Infection — Sub-Saharan Africa, 2000–20112014
- Natural History and Management of Hepatitis C: Does Sex Play a Role?The Journal of Infectious Diseases, 2014
- Prevention of mother-to-child transmission of hepatitis B virus and hepatitis C virusExpert Review of Anti-infective Therapy, 2014
- Hepatitis B: prevalence and pathophysiology.2014
- Hepatitis B and CClinics in Geriatric Medicine, 2014
- Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practiceHepatology, 2014
- Hepatitis B Management in Vulnerable Populations: Gaps in Disease Monitoring and Opportunities for Improved CareDigestive Diseases and Sciences, 2013